MarketVIEW Hospital / AMR Diseases  ·  2020 edition

Pseudomonas aeruginosa
Vaccines Forecast

Pseudomonas aeruginosa is now estimated to cause 559,000 deaths worldwide each year, more than 300,000 of them associated with antimicrobial resistance, and the pathogen still accounts for up to 23% of ICU infections, including ventilator-associated pneumonia, where mortality reaches as high as 43%. When VacZine Analytics last covered this market in 2020, the field's most advanced vaccine candidate was already in Phase II testing; both that vaccine, IC43, and a leading monoclonal antibody, AR-105, have since failed to meet their primary endpoints in confirmatory trials, resetting the field's hopes onto newer outer-membrane-vesicle platforms and CARB-X-backed multivalent candidates such as Vaxdyn's. This is a comprehensive, wide geography commercial assessment of the Pseudomonas aeruginosa vaccine opportunity, drawing on VacZine Analytics' long standing, independent authority in hospital-acquired and antimicrobial-resistant disease vaccine markets.

559,000 Deaths Worldwide Annually Vaxdyn Trivalent: Targeting First Human Data Nosocomial & Lung Disease Populations WHO High-Priority Resistant Pathogen
Product catalogue
VAMV010
2020 edition

Format
PDF + Excel model
Markets modelled
Nosocomial & lung disease populations
Scenarios
LO / BASE / HI pricing
Forecast horizon
To 2030
Approach
Value ($USD)/volume (000s) demand model
Base edition
2020 edition
Availability
Syndicated / bespoke
559,000
Deaths worldwide attributable
to P. aeruginosa each year
300,000+
Of those deaths directly
associated with AMR
Up to 23%
Of ICU infections (incl. VAP)
caused by P. aeruginosa
0
Licensed P. aeruginosa
vaccines available today
Disease background

A quantified burden, a partial resistance reprieve, and a reset vaccine field

This review sets out the current disease background, global AMR burden and R&D competitive landscape for Pseudomonas aeruginosa, drawing on the latest WHO and GRAM surveillance data.

WHO / GRAM 2025-2026 AMR surveillance update

Pathogen overview - Pseudomonas aeruginosa

Pseudomonas aeruginosa (PA) is primarily a nosocomial, Gram-negative pathogen, historically accounting for around 10% of all hospital-acquired infections (HAIs), second only to Staphylococcus aureus. PA infections are invasive and toxigenic, affecting a wide variety of patient groups but principally those with lung dysfunction, including ventilated ICU patients, chronic obstructive pulmonary disease and cystic fibrosis, alongside severe burns patients. In cystic fibrosis specifically, P. aeruginosa becomes the predominant airway pathogen in adulthood, outcompeting other microbes and driving progressive lung function decline. Although PA infections are treatable, many strains are multidrug-resistant (MDR) and associated with high mortality. When VacZine Analytics last published on this market in 2020, vaccine companies were investigating newer strategies after previous developmental prophylactic vaccines had failed, with the most advanced candidate then in Phase II testing.

The scale of that burden has since been quantified more precisely, even as the resistance picture has shown some tentative improvement. P. aeruginosa is now estimated to cause approximately 559,000 deaths worldwide each year, of which more than 300,000 are directly associated with antimicrobial resistance. The pathogen accounts for around 7% of HAIs worldwide and up to 23% of ICU infections, particularly ventilator-associated pneumonia (VAP), where mortality reaches 32% to 43%. WHO's 2024 Bacterial Priority Pathogens List nonetheless downgraded carbapenem-resistant P. aeruginosa (CRPA) from critical to high priority, reflecting an observed decline in resistance in at least one WHO region and its comparatively lower transmissibility relative to other carbapenem-resistant organisms, a rare piece of encouraging news against an otherwise persistent burden.

The vaccine field's own progress has been considerably less encouraging. IC43, the recombinant OprF/OprI fusion-protein vaccine that was the field's most advanced candidate at Phase II when VacZine Analytics last published this market, went on to a confirmatory Phase 2/3 trial in 800 mechanically ventilated ICU patients; it failed to meet its primary efficacy endpoint, with 28-day all-cause mortality of 29.2% in vaccinated patients against 27.7% on placebo. Aridis Pharmaceuticals' AR-105, a monoclonal antibody rather than a vaccine but developed as a complementary immunologic approach against the same VAP indication, also failed to demonstrate superiority over placebo on its primary clinical cure endpoint in Phase II testing. Attention has since shifted to newer outer-membrane-vesicle (OMV) platforms, including a STING-adjuvanted OMV nanoparticle candidate and a further recombinant OMV-based vaccine, both still in preclinical development, and to Vaxdyn's CARB-X-backed trivalent vaccine, which targets P. aeruginosa alongside Acinetobacter baumannii and Klebsiella pneumoniae and is targeting its own first proof of concept in humans.

2026 559,000 deaths/year worldwide  |  300,000+ AMR-associated  |  IC43 & AR-105 both failed Phase II endpoints  |  Vaxdyn trivalent targeting first human data  |  still no licensed vaccine
Product & competitor landscape

After two high-profile Phase II failures, hope shifts to multivalent OMV platforms

The field's two most advanced candidates when VacZine Analytics last published this market have both since failed to meet their primary endpoints. That reset has pushed the most credible near-term hope onto a new generation of multivalent, CARB-X-backed programmes.

  • Valneva SEPhase 2/3 confirmatory trial failed
    IC43 Recombinant OprF/OprI fusion-protein vaccine
    A confirmatory trial in 800 mechanically ventilated ICU patients failed to meet its primary efficacy endpoint, with 28-day mortality of 29.2% in vaccinated patients versus 27.7% on placebo.
  • Aridis PharmaceuticalsPhase 2 primary endpoint not met
    AR-105 Monoclonal antibody, not a vaccine
    A fully human IgG1 monoclonal antibody for VAP treatment that failed to demonstrate superiority over placebo on its primary Day 21 clinical cure endpoint.
  • Vaxdyn (CARB-X-backed)P. aeruginosa candidate still preclinical
    Trivalent Gram-negative vaccine candidate Multivalent: P. aeruginosa, A. baumannii & K. pneumoniae
    A single trivalent vaccine directed against three priority Gram-negative pathogens, the field's most credentialed near-term candidate following the IC43 and AR-105 setbacks. In September 2026 Vaxdyn raised €11m (Biovance Capital, Arcano Partners and the EIC Fund) to fund a Phase 1 trial of K-VAX, its Klebsiella pneumoniae/Acinetobacter baumannii candidate; the company's Pseudomonas-targeting candidate, P-VAX, remains in preclinical development.
  • Academic & industry research groupsPreclinical
    OMV-based & STING-adjuvanted nanoparticle candidates
    Newer outer-membrane-vesicle platforms, including a STING-adjuvanted OMV nanoparticle vaccine, remain in earlier-stage preclinical development.
Field reset
Phase II failed

IC43 and AR-105, the two most advanced immunologic approaches against Pseudomonas aeruginosa when VacZine Analytics last published this market, have both since failed to meet their primary endpoints in confirmatory trials, resetting expectations for the entire field. That reset has pushed the most credible near-term hope onto Vaxdyn's CARB-X-backed trivalent candidate, alongside newer OMV-based platforms still in preclinical development, even as P. aeruginosa continues to cause an estimated 559,000 deaths worldwide each year. The VacZine Analytics model quantifies the resulting opportunity under LO/BASE/HI forecast scenarios reflecting differing targeting, competitive and pricing assumptions across nosocomial and lung disease populations.

Scope of analysis

Six analytical layers - one commercial picture

This is a genuinely comprehensive report with a wide geographic focus, spanning disease burden, current R&D status and scenario-based demand forecasting across nosocomial and lung disease populations to 2030.

Nosocomial & lung disease population forecast

Value ($USD) and volume (000s) forecasts to 2030 across ICU, COPD, cystic fibrosis and burns patient populations.

Competitor & pipeline review

Full review of IC43's and AR-105's Phase II failures, Vaxdyn's trivalent candidate and the wider OMV-based R&D landscape.

TPP, targeting & pricing scenarios

LO/BASE/HI forecast scenarios reflecting differing targeting, competitive and pricing assumptions across all patient populations.

Cystic fibrosis & chronic infection review

Assessment of P. aeruginosa's role as the predominant CF airway pathogen and its distinct chronic-infection commercial profile.

Disease burden & epidemiology

Global mortality and AMR-attributable burden data updated through WHO and GRAM's most recent reporting.

Antimicrobial resistance & unmet need review

Assessment of the WHO priority pathogen downgrade, VAP mortality trends and the rationale for renewed vaccine investment.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the market-segment and scenario framework. Full volume/value outputs, pricing assumptions and patient-subset data are in the licensed model.

Market segmentGeographySectorVaccine statusRevenue scenario
ICU / mechanically ventilated (VAP)US, EU & major Western marketsHospital/publicPre-licensureModelled
Cystic fibrosis chronic infectionUS, EU & major Western marketsHospital/privatePre-licensureModelled
COPD & severe burns patientsUS, EU & major Western marketsHospital/publicPre-licensureModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseAll geographiesAll sectorsAll scenarios$███m
Full model in the licensed workbook
Nosocomial & lung disease populations · to 2030 · LO/BASE/HI scenarios
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for organisations evaluating the Pseudomonas aeruginosa vaccine opportunity across nosocomial and lung disease populations.

  • Executive presentation + forecast model (PDF + Excel) - disease background, epidemiology, R&D status and full commercial assessment with supporting narrative and references
  • MS-Excel forecast model - value ($USD) and volume (000s) predictions to 2030 across nosocomial and lung disease target populations
  • LO/BASE/HI forecast scenarios - three scenarios reflecting differing targeting, competitive and pricing assumptions
  • Competitor intelligence - IC43's and AR-105's Phase II failures, Vaxdyn's trivalent candidate and the wider OMV-based R&D landscape
  • Updated epidemiology module - WHO/GRAM 2025-2026 update covering AMR-attributable mortality, VAP burden and the WHO priority pathogen downgrade
  • Cystic fibrosis & unmet need review - the case for continued vaccine investment despite the field's recent high-profile Phase II setbacks
Target audience

Built for organisations weighing the Pseudomonas aeruginosa vaccine opportunity

Most valuable to teams evaluating the Pseudomonas aeruginosa vaccine market against their own pipeline, BD ambitions or investment thesis, now that the field's two most advanced candidates have both reported setbacks.

Vaccine & mAb developers

Positioning and commercial feasibility assessment for P. aeruginosa candidates at any stage, informed by the IC43 and AR-105 Phase II failures.

Corporate strategy & BD

Validate the size and structure of a still-open market with no incumbent vaccine, despite two high-profile late-stage setbacks.

Investors & analysts

Independent assessment of pipeline risk and commercial upside for due diligence on Vaxdyn, Valneva, Aridis and future entrants.

Hospital & infection-control leadership

Demand modelling and patient-group risk classification to support ICU, COPD and cystic fibrosis infection-prevention planning.

Researchers & academia

Comprehensive epidemiology, antimicrobial resistance and immunologic R&D landscape for grant and translational research planning.

Market access & policy

Pricing benchmarks and access-pathway assumptions across nosocomial and chronic lung disease channels.

About this analysis · VAMV010

VacZine Analytics has tracked hospital-acquired and antimicrobial-resistant disease vaccine markets since our earliest editions, positioning us to reassess the Pseudomonas aeruginosa vaccine opportunity the moment the field's two most advanced candidates both reported Phase II setbacks. This is a genuinely comprehensive analysis with a wide geographic focus spanning nosocomial and lung disease populations, and it has been well received by clients across the field for the depth of its epidemiology and scenario modelling. Few groups have followed this market as closely, and that recognised, independent expertise underpins everything in the analysis.

This report was last published in 2020. A refresh would incorporate WHO and GRAM's most recent AMR data, confirming 559,000 deaths worldwide attributable to P. aeruginosa each year, alongside IC43's and AR-105's confirmatory Phase II trial failures and the continued progress of Vaxdyn's CARB-X-backed trivalent candidate (P-VAX) as the field's most credentialed near-term prospect. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV010 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc Pseudomonas aeruginosa analysis, a briefing call is included on request.